Advanced searches left 3/3

CT - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 23 July 2022

* If you want to update the article please login/register

Evaluation of Breast CT

Breast cancer screening in the normal risk and high risk groups should be based on the findings of the clinical trials that were part of this review.

Source link: https://clinicaltrials.gov/ct2/show/NCT00584233


NHLBI-Emory Advanced Cardiac CT Reconstruction

The raw CT results are obtained in the course of a clinically supported time-resolved cardiac CT with no change in clinical practice. Candidates were selected clinically to perform time-resolved cardiac CT in the diagnosis and treatment of structural heart disease. Raw CT results used for standard medical care are copied after consenting in writing, data are extracted from their medical record, and clinical registry data are extracted. There is no investigational component to the standard clinical CT data collection, and there is no change in radiation exposure from routine clinical CT examination. The raw CT results are sent with PII to NHLBI analysts who will delete identifiers and replace them with code before releasing the image to the company collaborator for investigational advanced mathematical image reconstruction. The newly restored CT photographs are then posted at the NHLBI, where the images are re-identified. The newly restored photograph will then be delivered to the site investigators by the NHLBI investigators. The present research consisted of a comparison of standard CT images from the enrolling site with the advanced mathematical image reconstructions for quality metrics. The aim of this study is to determine whether advanced mathematical image reconstructions result in higher quality images in patients with structural heart disease. Endpoints: The primary endpoint is a semi-quantitative measure of superiority of advanced mathematical image reconstruction compared to standard cardiac CT image reconstruction for study-specific fine detail.

Source link: https://clinicaltrials.gov/ct2/show/NCT05372627


Methionine PET/CT Studies In Patients With Cancer

Secondary aim: To determine uptake of MET in tumors in patients with newly diagnosed or relapsed, as well as persistent disease. Both qualitatively and semi-quantitatively, hypothese: high grade tumors will have higher amounts of MET than lower grade tumors. Exploratory goals: To compare the results of MET PET scans with those of standard imaging techniques, primarily MRI and FDG PET CT at diagnosis, or at research enrollment for patients with relapsed and persistent disease in patients over time, as well as all patients over time.

Source link: https://clinicaltrials.gov/ct2/show/NCT00840047


18F-DCFPyL PET/CT in Hepatocellular Carcinoma

PSMA has been shown not only on prostate cancer cells but also on cell lines of other malignancies, as well as tumor endothelium. In the tumor vasculature, nearly 85% of hepatocellular carcinoma stained positive for PSMA, according to a recent study. Early and during HCC cell formation, the process of endothelial cell transplantation to HCC is crucial, according to research, making an endothelial cell tracer an excellent marker to detect early disease. This agent, along with the second generation PSMA PET agent, bonds with high adherence to PSMA, but this agent, as well as whole-body PET imaging, can provide a new method for staging high risk tumors and detecting recurrent disease. Participants > 18 years old Intending: Participants with suspected hepatocellular carcinoma by 18F-DCFPyL PET/CT imaging to find sites of hepatocellular carcinoma with at least one measurable lesion on standard imaging modality. Eastern Cooperative Oncology Group The aim is to determine sites of hepatocellular carcinoma with at least one measurable lesion on standard imaging modality. During the first routine follow-up period, usually within 4-8 weeks, participants with a baseline positive 18F-DCFPyL-PET/CT imaging and biopsy confirming HCC diagnosis will undergo a post-treatment 18F-DCFPyL-PET/CT imaging and biopsy confirming HCC diagnosis will undergo a post-treatment 18F-DCFPyL-PET/CT imaging and biopsy confirming HCC diagnosis will undergo a post-treatment 18F-DCFPyL-PET/CT/W a et period, typically within 4-8 weeks. The 18F-DCFPyL-PET/CT baseline will not be re-scanned post-treatment, but it will remain in a sequel. Participants with a positive HCC biopsy will be followed for 5 years to see if progression free survival is possible.

Source link: https://clinicaltrials.gov/ct2/show/NCT05009979


SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making

To determine the effect of technetium Tc-99 million sestamibi SPECT/CT on patient management decisions, the researcher must investigate. To determine the effect of MIBI SPECT/CT on decisional conflict score, we will need to determine the effect of the MIBI SPECT/CT on decisional conflict score. To determine whether MIBI SPECT/CT can be used to identify an oncocytic renal mass with respect to tumor histology diagnosed by renal mass biopsy or surgical resection, it is important to determine the sensitivity and specificity of the procedure. To determine an oncocytic renal mass, we used MIBI SPECT/CT with traditional cross-sectional imaging. Evaluate the mitochondria content in tumors with positive MIBI SPECT/CT findings. Patients receive technetium Tc-99 million sestamibi intravenously and then undergo SPECT/CT.

Source link: https://clinicaltrials.gov/ct2/show/NCT03996850


18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

BACKGROUND PROstate cancer is the second most common cause of cancer death in American men. An initial test of F-DCFBC, a first-generation PET agent focusing on PSMA, showed the ability of PET to find points of recurrence in patients with advanced local disease and biochemically recurrent prostate cancer, but it was hindered by a lack of blood pool activity. F-DCFPyL, a second generation PSMA PET agent, has binds with high affinity to PSMA but clears rapidly from the blood pool and, consequently, whole-body PET imaging with this agent could be a new tool in diagnosing high risk cancers and detecting recurrent disease. Primary Target - To determine the ability of F-DCFPyL to accurately assess high-risk primary prostate cancer and detect sites of recurrent prostate cancer. Up to five eligible patients in cohort 2 will be treated with an additional 18F-DCFPyL PET/CT scan within 1 month of the first study, following unilateral salivary gland cannulation and the introduction of unlabeled DCFPyL into the cannulated gland. Patients from cohort 2 who have a positive 18F-DCFPyL PET/CT scan at any time may also have a one-time 18F-FDG PET/CT within 30 days of the positive 18F-DCFPyL PET/CT findings.

Source link: https://clinicaltrials.gov/ct2/show/NCT03181867


PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2

The radioligand 68Ga-NODAGA-E [c]2 hits the Arg-Gly-Asp sequence, which is known to bind to the u03b1vu03b23 integrin, which is present on the surface of angiogenic blood vessels or tumor cells. Standardized Uptake Values and compared to PFS, DSS, and OS will be standardizedized, so the uptake of 68Ga-NODAGA-E[c]2 in tumor lesions will be quantified.

Source link: https://clinicaltrials.gov/ct2/show/NCT03271281


Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis

Introduction: acute myocarditis diagnosis is difficult in a particular population of patients with no obvious risk factors for atheromatous disease. Both cardiac MRI and coronary angiography are often used for the definitive diagnosis of myocarditis and the ruling out a coronary artery disease. Spectral cardiac CT could be particularly useful in the diagnosis of acute chest pain in this specific group of patients with low cardiovascular risk factors. It also allows the direct visualization of coronary arteries, avoiding the need of doing coronary angiography in a large number of patients with acute chest pain. In patients with acute chest pains, the primary aim is to determine the diagnostic accuracy of spectral cardiac CT imaging for the diagnosis of acute myocarditis using cardiac MRI as the gold standard. The diagnosis of acute myocarditis using spectral cardiac CT scan will be based on a late subepicardial contrast enhancement seen using iodine imaging obtained after subtraction of water imaging. Secondary aim: To determine the radiation dose in a spectral cardiac CT scan using the most recent generation of machines from various manufacturers. Cardiac MRI serves as the gold standard for definitive diagnosis of acute myocarditis. To minimize work-up bias, all patients will be tested with cardiac CT scan with spectral mode detection and cardiac MRI.

Source link: https://clinicaltrials.gov/ct2/show/NCT02905721

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions